Ep_2 - Dr Sarah Diermeier - Druggable targets in DNA "Dark Matter"

Dr Sarah Diermeier is a pioneer in the world of RNA therapeutics.

Armed with a PhD, she completed a post-doctoral research fellowship at the prestigious Cold Spring Harbour Laboratory in Long Island New York, before re-locating to New Zealand with her family to take up a tenured role at Otago University and founding Amaroq Therapeutics.

Amaroq is a Venture-backed, pre-clinical, biotech start-up leveraging recent findings in long non-coding RNA to develop next generation RNA therapeutics in oncology.

Join us in Episode 2 where Sarah and I discuss why our "junk" DNA may not be junk after all, what lncRNA is and why it took 60 years to discover, and what her company Amaroq is doing to leverage recent findings in the field lncRNA to develop novel drugs for treatment of various cancers.

You can find out more about Sarah and Amaroq here: https://www.linkedin.com/in/sdiermeier/ https://www.linkedin.com/company/amaroqtx/ https://amaroqtx.com/about/ https://twitter.com/oncogenie